Literature DB >> 12578839

Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site.

Hitoshi Sawaoka1, Dan A Dixon, John A Oates, Olivier Boutaud.   

Abstract

In human colorectal adenocarcinoma cell lines, we found two major transcripts of cyclooxygenase-2, the full-length mRNA and a short polyadenylation variant (2577 kb) lacking the distal segment of the 3'-untranslated region. Tristetraprolin, an mRNA-binding protein that promotes message instability, was shown to bind the cyclooxygenase-2 mRNA in the region of the 3'-untranslated region between nucleotides 3125 and 3432 and to reduce levels of the full-length mRNA. During cell growth and confluence, the expression of tristetraprolin mRNA was inversely correlated with that of the full-length cyclooxygenase-2 transcript, and transfection of tristetraprolin into HCA-7 cells reduced the level of full-length cyclooxygenase-2 mRNA. However, the truncated transcript escaped tristetraprolin binding and downregulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578839     DOI: 10.1074/jbc.M300016200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

Review 1.  The roles of TTP and BRF proteins in regulated mRNA decay.

Authors:  Sandhya Sanduja; Fernando F Blanco; Dan A Dixon
Journal:  Wiley Interdiscip Rev RNA       Date:  2011 Jan-Feb       Impact factor: 9.957

2.  Posttranscriptional regulation of IL-23 expression by IFN-gamma through tristetraprolin.

Authors:  Xuesong Qian; Huan Ning; Jidong Zhang; Daniel F Hoft; Deborah J Stumpo; Perry J Blackshear; Jianguo Liu
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

3.  Herpes simplex virus 1 induces cytoplasmic accumulation of TIA-1/TIAR and both synthesis and cytoplasmic accumulation of tristetraprolin, two cellular proteins that bind and destabilize AU-rich RNAs.

Authors:  Audrey Esclatine; Brunella Taddeo; Bernard Roizman
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

4.  The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2.

Authors:  Lisa E Young; Ashleigh E Moore; Lena Sokol; Nicole Meisner-Kober; Dan A Dixon
Journal:  Mol Cancer Res       Date:  2011-11-02       Impact factor: 5.852

5.  Molecular identification of the gene encoding porcine tristetraprolin (TTP).

Authors:  Zheng-Bing Guan; Yan Shui; Jian Lu
Journal:  Mol Cell Biochem       Date:  2010-08-19       Impact factor: 3.396

Review 6.  Inflammation: cytokines and RNA-based regulation.

Authors:  Deborah J Stumpo; Wi S Lai; Perry J Blackshear
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

7.  Suppression of IL-12 production by tristetraprolin through blocking NF-kcyB nuclear translocation.

Authors:  Ling Gu; Huan Ning; Xuesong Qian; Qi Huang; Rong Hou; Rajaa Almourani; Mingui Fu; Perry J Blackshear; Jianguo Liu
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

8.  cAMP-dependent posttranscriptional regulation of steroidogenic acute regulatory (STAR) protein by the zinc finger protein ZFP36L1/TIS11b.

Authors:  Haichuan Duan; Nadia Cherradi; Jean-Jacques Feige; Colin Jefcoate
Journal:  Mol Endocrinol       Date:  2009-01-29

9.  MSK1 and MSK2 inhibit lipopolysaccharide-induced prostaglandin production via an interleukin-10 feedback loop.

Authors:  Kirsty F MacKenzie; Mirjam W M Van Den Bosch; Shaista Naqvi; Suzanne E Elcombe; Victoria A McGuire; Alastair D Reith; Perry J Blackshear; Jonathan L E Dean; J Simon C Arthur
Journal:  Mol Cell Biol       Date:  2013-02-04       Impact factor: 4.272

10.  Structural and functional dissection of a conserved destabilizing element of cyclo-oxygenase-2 mRNA: evidence against the involvement of AUF-1 [AU-rich element/poly(U)-binding/degradation factor-1], AUF-2, tristetraprolin, HuR (Hu antigen R) or FBP1 (far-upstream-sequence-element-binding protein 1).

Authors:  Gareth Sully; Jonathan L E Dean; Robin Wait; Lesley Rawlinson; Tomas Santalucia; Jeremy Saklatvala; Andrew R Clark
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.